GENinCode PLC on Thursday said its risk of ovarian cancer risk test has been recommended as preferred test in England.
Shares in the Oxford-based biotechnology company focused on prevention of cardiovascular disease jumped 46% to 5.11 pence each on Thursday around noon in London.
The company said the National Institute for Health & Care Excellence recommended GENinCode’s risk of ovarian cancer, or ROCA, test as preferred test for ovarian cancer surveillance in people at high risk of ovarian cancer who do not undertake risk reducing surgery.
The new NICE guidance is focused on identifying and managing familial and genetic risk of ovarian cancer, GENinCode explained.
‘Each year in the UK, 7,500 women are diagnosed with OC and over half of those will die from the disease. The risk of developing OC is particularly high in individuals who inherit a known pathogenic variant in certain genes such as BRCA1 or BRCA2. It is estimated that up to 170,000 people in the UK may be carriers of a BRCA gene variant. Identifying such individuals through genetic testing will allow the NHS to better mitigate that risk through prevention and/or surveillance,’ GENinCode said.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
